Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier Sutter

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Cancers|March 6, 2021
Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score AnalysisGaël S Roth, Maxime Benhamou, Yann Teyssier, et al.
Journal of Hepatology|December 25, 2019
Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCsAnita Paisant, Valérie Vilgrain, Jérémie Riou, et al.
Clinics and Research in Hepatology and Gastroenterology|June 17, 2021
Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasionLorraine Blaise, Helena Pereira, Valérie Vilgrain, et al.
Clinics and Research in Hepatology and Gastroenterology|July 31, 2021
Non-invasive diagnosis and follow-up of primary malignant liver tumoursPierre Nahon, Christophe Aubé, Lucile Moga, et al.
World Journal of Gastroenterology|October 3, 2022
Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolizationGael Roth, Yann Teyssier, Maxime Benhamou, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 22, 2018
Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosisManon Allaire, Samia Rekik, Richard Layese, et al.
Hepatology (Baltimore, Md.)|October 23, 2023
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Ariane Vallot, Haroun Ghannouchi, et al.
Scientific Reports|November 5, 2022
Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablationElia Gigante, Yohann Haddad, Jean-Charles Nault, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2021
Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver diseaseNga Nguyen, Agnès Rode, Hervé Trillaud, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 29, 2022
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Jessica Bamba-Funck, Bertille Campion, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Cancers|March 6, 2021
Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score AnalysisGaël S Roth, Maxime Benhamou, Yann Teyssier, et al.
Journal of Hepatology|December 25, 2019
Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCsAnita Paisant, Valérie Vilgrain, Jérémie Riou, et al.
Clinics and Research in Hepatology and Gastroenterology|June 17, 2021
Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasionLorraine Blaise, Helena Pereira, Valérie Vilgrain, et al.
Clinics and Research in Hepatology and Gastroenterology|July 31, 2021
Non-invasive diagnosis and follow-up of primary malignant liver tumoursPierre Nahon, Christophe Aubé, Lucile Moga, et al.
World Journal of Gastroenterology|October 3, 2022
Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolizationGael Roth, Yann Teyssier, Maxime Benhamou, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 22, 2018
Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosisManon Allaire, Samia Rekik, Richard Layese, et al.
Hepatology (Baltimore, Md.)|October 23, 2023
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Ariane Vallot, Haroun Ghannouchi, et al.
Scientific Reports|November 5, 2022
Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablationElia Gigante, Yohann Haddad, Jean-Charles Nault, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2021
Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver diseaseNga Nguyen, Agnès Rode, Hervé Trillaud, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 29, 2022
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Jessica Bamba-Funck, Bertille Campion, et al.
Pageof 6